Compare BANF & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BANF | CPRX |
|---|---|---|
| Founded | 1984 | 2002 |
| Country | United States | United States |
| Employees | 2260 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.4B |
| IPO Year | N/A | 2006 |
| Metric | BANF | CPRX |
|---|---|---|
| Price | $115.91 | $31.38 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $124.00 | $35.00 |
| AVG Volume (30 Days) | 125.5K | ★ 2.0M |
| Earning Date | 04-16-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.76% | N/A |
| EPS Growth | N/A | ★ 28.24 |
| EPS | N/A | ★ 0.50 |
| Revenue | N/A | ★ $119,072,803.00 |
| Revenue This Year | $6.10 | $9.20 |
| Revenue Next Year | $3.92 | $10.51 |
| P/E Ratio | ★ $16.38 | $62.74 |
| Revenue Growth | N/A | ★ 16.39 |
| 52 Week Low | $101.48 | $19.05 |
| 52 Week High | $138.15 | $32.56 |
| Indicator | BANF | CPRX |
|---|---|---|
| Relative Strength Index (RSI) | 63.45 | 73.15 |
| Support Level | $106.29 | $31.25 |
| Resistance Level | $122.05 | $32.56 |
| Average True Range (ATR) | 2.50 | 0.05 |
| MACD | 0.70 | -0.17 |
| Stochastic Oscillator | 92.49 | 83.33 |
BancFirst Corp is engaged in providing banking services. The company's business unit includes BancFirst metropolitan banks, BancFirst community banks, Pegasus Bank, Worthington, other financial services and executive, operations and support. BancFirst metropolitan banks, BancFirst community banks, Pegasus and Worthington offer traditional banking products such as commercial and retail lending and a full line of deposit accounts. Its Other financial services are specialty product business units including guaranteed small business lending, residential mortgage lending, trust services, securities brokerage, electronic banking, and insurance.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.